List of Excipients in Branded Drug ORTHO MICRONOR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	ORTHO MICRONOR	norethindrone	50458-194	D&C GREEN NO. 5
Janssen Pharmaceuticals Inc	ORTHO MICRONOR	norethindrone	50458-194	D&C YELLOW NO. 10
Janssen Pharmaceuticals Inc	ORTHO MICRONOR	norethindrone	50458-194	LACTOSE
Janssen Pharmaceuticals Inc	ORTHO MICRONOR	norethindrone	50458-194	MAGNESIUM STEARATE
Janssen Pharmaceuticals Inc	ORTHO MICRONOR	norethindrone	50458-194	MODIFIED CORN STARCH
Janssen Pharmaceuticals Inc	ORTHO MICRONOR	norethindrone	50458-194	POVIDONE

Ortho Micronor Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: October 29, 2026

Ortho Micronor is a legacy progestin-only oral contraceptive containing norethindrone 0.35 mg per tablet. Its commercial opportunity is no longer based on blocking generic norethindrone tablets. The opportunity is in differentiated delivery, excipient tolerance, packaging, adherence, and lifecycle products that can support an ANDA, 505(b)(2) application, or branded over-the-counter-adjacent strategy where permitted by FDA requirements.

The core formulation is technically simple: a low-dose immediate-release tablet supplied in a 28-day regimen without a tablet-free interval. The commercial challenge is dose uniformity at 0.35 mg, patient adherence, competing low-cost generics, and limited room for excipient-driven differentiation. FDA approval of norethindrone tablets and the absence of a meaningful current Orange Book patent barrier leave formulation and regulatory execution as the principal sources of value.[1-3]

What is Ortho Micronor and how is it formulated?

Ortho Micronor contains norethindrone, a synthetic progestin, at 0.35 mg per tablet. It is a progestin-only oral contraceptive intended for daily administration at the same time each day.[1]

Attribute	Ortho Micronor
Active ingredient	Norethindrone
Strength	0.35 mg per tablet
Dosage form	Immediate-release oral tablet
Regimen	One tablet daily for 28 consecutive days
Estrogen	None
Therapeutic category	Progestin-only oral contraceptive
Original sponsor	Ortho Pharmaceutical, later associated with Johnson & Johnson/Janssen
FDA pathway	NDA-based branded product; generic products approved through ANDAs
Current competitive structure	Generic norethindrone 0.35 mg tablets
Primary formulation issue	Uniform distribution of a very low-dose active ingredient

Historical Ortho Micronor labeling identifies conventional tablet excipients, including lactose, starch and magnesium stearate, although the exact qualitative and quantitative composition may vary by product version and manufacturer.[1] Generic formulations should be assessed individually because inactive ingredients, imprinting, colorants, packaging and manufacturing controls can differ.

Why does the 0.35 mg dose matter?

Norethindrone represents a small fraction of tablet mass. That creates formulation risk around:

• Content uniformity.
• Blend segregation.
• Assay variability.
• Compression-force effects.
• Dissolution performance.
• Stability under heat and humidity.
• Scale-up from laboratory blending to commercial manufacture.

A low-dose formulation typically requires strong control of particle-size distribution, premixing, geometric dilution, blend time and sampling strategy. Direct compression may be commercially attractive, but wet granulation can offer better content-uniformity control where the active has poor flow or poor distribution in the excipient matrix.

What excipients are used in Ortho Micronor and generic norethindrone tablets?

The conventional excipient platform uses a diluent, a binder or disintegrant system, and a lubricant. Lactose supplies bulk, starch supports tablet breakup and may assist binding, while magnesium stearate reduces sticking during compression.[1]

The relevant excipient decisions are:

Excipient function	Conventional choice	Commercial rationale	Principal risk
Diluent	Lactose	Low cost, established oral-tablet use	Lactose intolerance positioning and supplier variability
Disintegrant or binder	Starch or pregelatinized starch	Established performance and low cost	Variable compression and disintegration behavior
Lubricant	Magnesium stearate	Effective at low concentration	Overlubrication may slow dissolution
Alternative diluent	Microcrystalline cellulose	Strong compaction and lactose-free positioning	Higher cost and different mouthfeel
Superdisintegrant	Crospovidone or croscarmellose sodium	Faster disintegration and potential small-tablet design	Moisture sensitivity and formulation complexity
Flow aid	Colloidal silicon dioxide	Improved flow for low-dose blends	Dust handling and overuse risk
Film coat	Hypromellose-based coating	Branding, swallowability and moisture protection	Added process cost and potential dissolution effects

The objective should not be to add excipients without a defined product claim. A new excipient platform has commercial value only if it supports one of four outcomes: better dose uniformity, better adherence, broader patient acceptability, or a differentiated regulatory position.

What excipient strategies could differentiate an Ortho Micronor successor?

Lactose-free formulation

A lactose-free norethindrone tablet could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate or a multifunctional co-processed excipient. The strongest commercial rationale is patient-label simplification and broader excipient tolerance, not a claim that the current product is clinically unsuitable.

A lactose-free version would have to preserve:

• 0.35 mg dose uniformity.
• Immediate-release dissolution.
• Tablet hardness sufficient for packaging and transport.
• Low friability.
• Stable potency through the proposed shelf life.
• Equivalent or acceptable bioavailability.

Mannitol could also support a more patient-friendly mouthfeel, but its hygroscopicity and compression characteristics require evaluation. Microcrystalline cellulose is a more conventional solid-dose platform and may be easier to scale.

Low-moisture formulation

Norethindrone products can be positioned for climates and distribution channels where humidity control is a concern. A low-moisture excipient system, high-barrier blister, or desiccant-enabled bottle may provide more defensible value than a minor excipient substitution.

Potential approaches include:

• Low-water-content excipients.
• Moisture-barrier film coating.
• Aluminum-aluminum blister packaging.
• Unit-dose pouching.
• Desiccant canister packaging.
• Oxygen and humidity ingress testing under ICH conditions.

Packaging patents may be more commercially useful than composition claims if the tablet composition remains close to established generic formulations.

Fast-disintegrating or orally disintegrating tablet

An orally disintegrating norethindrone tablet could target patients with swallowing difficulty or users seeking more convenient administration. The formulation would need to address taste, mechanical fragility and dose uniformity.

Candidate excipient systems include:

• Mannitol for mouthfeel.
• Crospovidone or croscarmellose sodium for rapid breakup.
• Low-level flavoring or taste-masking agents.
• Direct-compression excipient blends.
• Specialized blister packaging.

This route may support a 505(b)(2) strategy if the product relies on a changed dosage form, labeling, or delivery profile. It would not automatically avoid an ANDA pathway. FDA determines the appropriate pathway based on the product’s relationship to the reference listed drug and the extent of formulation and labeling differences.[4]

Chewable tablet

A chewable product could support a new adherence proposition, but norethindrone taste and dose precision are substantial barriers. The formulation would require robust taste masking without materially changing dissolution or absorption.

Potential technologies include:

• Polymer-coated drug particles.
• Ion-exchange resin complexes.
• Lipid-based taste masking.
• Functional coating systems.
• Sweetener and flavor combinations.

A chewable formulation may be more patentable than a conventional tablet, but it carries higher development and regulatory risk. The commercial opportunity depends on demonstrating patient preference or adherence improvement rather than relying solely on a new dosage form.

Excipient system for low-dose content uniformity

The most technically relevant formulation opportunity is a platform that distributes 0.35 mg of norethindrone uniformly throughout a robust tablet blend. Possible strategies include:

1. Drug layering onto a carrier.
2. Premixing norethindrone with a portion of the diluent.
3. Granulation of the active with a controlled binder solution.
4. Use of co-processed excipients.
5. Controlled particle-size engineering.
6. Segregation-resistant packaging and handling.

A patent claim directed only to lactose substitution may be weak. A stronger claim could combine the excipient ratio, manufacturing sequence, particle-size profile, content-uniformity range, dissolution profile and stability result.

What patents protect Ortho Micronor and generic norethindrone tablets?

The original composition and product patents for a 0.35 mg norethindrone tablet are legacy rights and do not provide a practical barrier to generic entry. FDA’s Orange Book should be reviewed for the current NDA and any listed patents, but the commercial market is dominated by generic norethindrone products rather than a live Ortho Micronor patent moat.[2]

IP category	Likely status for legacy Ortho Micronor	Value for a new entrant
Original norethindrone composition claims	Expired or commercially irrelevant	Low
Conventional immediate-release tablet claims	Expired or difficult to enforce broadly	Low
Method-of-use contraception claims	Generally old and crowded	Low to moderate
Lactose/starch/magnesium stearate composition	Vulnerable to design-around	Low
ODT or chewable formulation	Potentially protectable	Moderate
Taste-masking technology	Potentially protectable	Moderate to high
Moisture-barrier packaging	Potentially protectable	Moderate
Manufacturing process for content uniformity	Potentially protectable if technically specific	Moderate
Novel excipient combination	Potentially protectable	Moderate
Device-enabled adherence system	Potentially protectable	Moderate

A new formulation patent should avoid claiming a generic tablet at the level of “norethindrone plus a pharmaceutically acceptable excipient.” Such claims face validity and infringement problems. Better claim structures include defined ranges, process limitations, functional performance parameters and comparative data.

When does Ortho Micronor lose exclusivity and what is the generic-entry risk?

The original branded product has already lost practical market exclusivity. Generic norethindrone 0.35 mg tablets are available through ANDA approvals, and the product category has no meaningful data-exclusivity barrier comparable to a recently approved innovative medicine.[2,3]

Paragraph IV challenges

Paragraph IV litigation is generally not the central risk for a legacy product with an expired or nonblocking patent estate. A generic applicant may file a Paragraph IV certification only when an Orange Book-listed patent remains relevant. For Ortho Micronor, the more important competitive question is whether a new branded formulation creates a patent estate that can withstand an ANDA challenge.

A formulation sponsor should assume:

• Conventional excipient substitutions will be easy to design around.
• A listed formulation patent may attract Paragraph IV litigation.
• Narrow process claims may be difficult to assert against an ANDA applicant.
• Product-by-process limitations have limited value unless the final product cannot be distinguished by other means.
• A new dosage form may generate a more durable but still challengeable patent position.

What is the FDA regulatory status of Ortho Micronor and norethindrone tablets?

Ortho Micronor was approved as an oral progestin-only contraceptive. FDA-approved generic norethindrone tablets use the ANDA framework where the applicant demonstrates pharmaceutical equivalence and bioequivalence to the reference listed drug.[2-4]

Regulatory considerations for an excipient-led product include:

Product change	Likely regulatory relevance
Change in filler within a conventional tablet	Usually compatible with an ANDA if equivalence requirements are met
Lactose-free reformulation	May fit an ANDA if pharmaceutical equivalence is maintained
New strength	May require a different regulatory strategy
New dosage form	Potential 505(b)(2) issue
Chewable tablet	May require new clinical, labeling or performance support
ODT	May require dosage-form-specific performance and bioequivalence assessment
New indication	Likely requires a separate regulatory strategy
New packaging only	May be handled through postapproval or product-specific requirements
Novel excipient	Higher regulatory and safety-review burden

The FDA’s product-specific guidance and current reference-listed-drug status must control development decisions. Excipient changes cannot be evaluated separately from dissolution, bioequivalence, stability, labeling and manufacturing controls.[4]

How strong is the Ortho Micronor patent estate?

The estate is weak for blocking conventional generic tablets and potentially valuable only for newly developed delivery or manufacturing technologies.

Strength factors

A new Ortho Micronor-related patent program would be stronger if it included:

• A clearly defined formulation composition.
• A reproducible content-uniformity advantage.
• Stability data under accelerated and long-term conditions.
• A distinct dissolution profile tied to clinical or regulatory performance.
• A nonobvious excipient interaction.
• Claims covering both composition and process.
• Claims covering commercial packaging.
• Freedom from dependence on a single excipient supplier.

Weakness factors

The estate would be weak if it relied on:

• Routine replacement of lactose with microcrystalline cellulose.
• Broad claims to norethindrone and any excipient.
• Conventional starch and magnesium stearate systems.
• Unclaimed manufacturing parameters.
• No evidence of improved stability or uniformity.
• A product that is indistinguishable from existing generics.

Which companies are challenging Ortho Micronor commercially?

The relevant competitive set is generic manufacturers of norethindrone 0.35 mg tablets rather than companies pursuing a direct patent challenge to an active Ortho Micronor estate. Generic contraceptive suppliers compete primarily on price, wholesaler access, pharmacy coverage, supply reliability and packaging.

The competitive landscape includes:

• Authorized generic or legacy-branded supply channels.
• ANDA holders for norethindrone 0.35 mg tablets.
• Women’s-health specialty pharmaceutical companies.
• Digital-health companies that pair prescription contraception with telehealth and adherence tools.
• Developers of long-acting reversible contraceptives.
• Manufacturers of combined oral contraceptives and other progestin-only products.

A differentiated norethindrone product must compete against both low-cost tablets and products that reduce daily adherence burden, including implants, intrauterine systems and longer-acting hormonal options.

What commercial opportunities exist for an excipient-led Ortho Micronor product?

Opportunity ranking

Opportunity	Technical complexity	Regulatory complexity	Commercial potential
Lactose-free immediate-release tablet	Low to moderate	Low to moderate	Moderate
Moisture-resistant blister presentation	Moderate	Low to moderate	Moderate
Small swallowable tablet	Moderate	Moderate	Moderate
Orally disintegrating tablet	Moderate to high	Moderate to high	Moderate to high
Chewable taste-masked tablet	High	High	Selective
Unit-dose adherence packaging	Moderate	Low to moderate	Moderate
Novel excipient platform	Moderate to high	Moderate to high	Moderate
Combination with digital adherence support	Moderate	Moderate	Moderate to high
Long-acting norethindrone delivery	High	High	High, but no longer a simple Ortho Micronor lifecycle product

Revenue exposure

The legacy brand’s revenue exposure is limited by generic substitution and the age of the product. Public filings and commercial databases should be used to quantify current brand sales, payer mix and prescription volume. A business case should not assume that historical Ortho Micronor sales translate into demand for a reformulated product.

A differentiated product can command a premium only if it produces a measurable benefit in one of these areas:

• Fewer missed doses.
• Better tolerability.
• Easier swallowing.
• Improved supply reliability.
• Lower packaging waste.
• Broader patient eligibility based on excipient profile.
• Better pharmacy or payer coverage.

What manufacturing and IP barriers affect commercialization?

The main manufacturing barriers are not the cost of norethindrone. They are low-dose blending, segregation control, analytical sensitivity, stability, and validated scale-up.

Critical development controls include:

• Assay and content-uniformity sampling plans.
• Blend uniformity across beginning, middle and end of discharge.
• Particle-size monitoring.
• Lubrication-time control.
• Tablet hardness and friability.
• Dissolution under discriminatory conditions.
• Moisture uptake.
• Extractables and leachables for new packaging.
• Cleaning validation for a potent low-dose hormonal product.
• Cross-contamination controls in multiproduct facilities.

The IP strategy should combine formulation patents with process, packaging and adherence claims. A single conventional composition patent is unlikely to create durable market protection.

What generic launch scenarios exist for a new Ortho Micronor formulation?

Scenario 1: Conventional generic tablet

This is the lowest-risk path and the lowest-margin opportunity. Price competition would be immediate, and the product would need manufacturing cost and supply advantages.

Scenario 2: Lactose-free or excipient-sensitive product

This offers a modest differentiation claim and may support specialty-pharmacy positioning. The main risk is that patients and prescribers may not pay a premium for the change.

Scenario 3: ODT or chewable product

This creates a more visible product distinction and a stronger lifecycle-management case. Development costs, taste masking and bioequivalence requirements are higher.

Scenario 4: Adherence-centered product

A unit-dose calendar pack, blister system, reminder-enabled package or digital companion could create commercial differentiation without materially changing the tablet. The strongest claims may reside in packaging and system patents rather than the excipient composition.

Scenario 5: 505(b)(2) reformulation

A sponsor could pursue a changed dosage form or delivery profile where the scientific and commercial case supports reliance on existing norethindrone safety and efficacy information. This route has greater regulatory cost but may support a differentiated label and stronger patent position.[4]

Key Takeaways

• Ortho Micronor is a 0.35 mg norethindrone immediate-release progestin-only tablet.
• The legacy product has no meaningful blocking patent position against conventional generic tablets.
• The central technical challenge is uniform distribution of a very low-dose active ingredient.
• Lactose-free, moisture-resistant, ODT, chewable and adherence-oriented products offer the clearest lifecycle opportunities.
• A simple excipient substitution is unlikely to support durable premium pricing or strong patent protection.
• The strongest new IP would combine composition, process, performance and packaging claims.
• Generic competition is already established, so commercial success depends on a measurable patient, payer or supply-chain benefit.
• A 505(b)(2) pathway may be relevant for a materially changed dosage form, but an ANDA remains the lower-complexity route for a conventional equivalent tablet.

FAQs

Is Ortho Micronor the same as norethindrone 0.35 mg generic tablets?

They contain the same active ingredient and strength, but inactive ingredients, manufacturing processes, imprinting and packaging may differ by manufacturer.

Can a lactose-free norethindrone tablet receive separate patent protection?

Yes, but a broad lactose-free claim may be vulnerable if lactose substitution is routine. Protection is stronger when the formulation produces a demonstrated technical effect, such as improved content uniformity, stability or dissolution.

Does Ortho Micronor have an active Orange Book patent?

The legacy product does not provide a meaningful practical patent barrier to established generic norethindrone tablets. Current Orange Book records should govern any product-specific patent determination.[2]

Is an orally disintegrating norethindrone product automatically a 505(b)(2) product?

No. FDA determines the appropriate pathway based on the dosage form, formulation, labeling and relationship to the reference listed drug. An ODT may require a 505(b)(2) application, but the pathway cannot be assumed solely from the dosage form.[4]

What is the most defensible excipient strategy for a new norethindrone product?

A formulation combining low-dose content-uniformity controls, a defined lactose-free or moisture-resistant excipient system, validated dissolution performance and differentiated unit-dose packaging offers the strongest balance of technical feasibility and commercial defensibility.

References

1. U.S. Food and Drug Administration. (n.d.). Ortho Micronor (norethindrone) tablets prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2019). ANDAs for certain highly variable drugs: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-certain-highly-variable-drugs

5. U.S. Food and Drug Administration. (2017). M9 biopharmaceutics classification system-based biowaivers: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m9-biopharmaceutics-classification-system-based-biowaivers

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.